Multiple Myeloma | Specialty

The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.

Talquetamab Plus Teclistamab Displays Activity in R/R Multiple Myeloma With True EMD

December 8th 2025

Talquetamab plus teclistamab produced a high ORR and CR or better rate in relapsed/refracotry multiple myeloma with true extramedullary disease.

Linvoseltamab Generates Responses in Newly Diagnosed Myeloma

December 8th 2025

Linvoseltamab monotherapy produced responses and was safe in newly diagnosed multiple myeloma.

Dual BCMA/CD19 CAR T-Cell Therapy AZD0120 Shows Promise for Multiple Myeloma

December 8th 2025

AZD0120 CAR T therapy shows rapid, deep responses and manageable safety in R/R myeloma, with ultra-fast manufacturing and strong early durability.

CAMMA 3 Data Support Ongoing Investigation of Cevostamab in Heavily Pretreated Myeloma

December 8th 2025

Subcutaneous cevostamab demonstrated activity and safety in patients with multiple myeloma who had received a median of 5 prior lines of therapy.

Dr Patel on the Efficacy of Anitocabtagene Autoleucel in R/R Multiple Myeloma

December 8th 2025

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.

Gintemetostat Shows Early Activity and Manageable Safety in Triple-Class Refractory Multiple Myeloma

December 7th 2025

Gintemetostat demonstrates efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.

KRd Demonstrates Superior PFS vs VRd in Newly Diagnosed Myeloma

December 6th 2025

KRd improved PFS, deepened responses, and led to higher MRD negativity vs VRd in newly diagnosed multiple myeloma.

Long-Term CARTITUDE-4 Data Point to Potential Cure Fraction With Cilta-Cel in Standard-Risk R/R Myeloma

December 6th 2025

In the CARTITUDE-4 trial, 80.5% of patients with standard-risk multiple myeloma were progression-free at 2.5 years after receiving cilta-cel.

Elranatamab Plus Iberdomide Shows Early Efficacy in R/R Multiple Myeloma

December 6th 2025

Elranatamab plus iberdomide showed a 95.5% response rate in patients with BCMA-naive relapsed/refractory myeloma per early MagnetisMM-30 data.

Early Use of Cilta-Cel Is Linked to Stronger Outcomes Due to Immune Fitness in R/R Myeloma

December 6th 2025

Administering cilta-cel earlier in treatment improves clinical outcomes, with superior PFS and OS rates compared to later intervention.

Previewing Top Myeloma Abstracts Set to Make Waves at ASH 2025

December 5th 2025

A look at the top multiple myeloma abstracts set to be presented at the 2025 ASH Annual Meeting.

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma

December 4th 2025

Larry Anderson, MD, PhD, FACP, discusses data from AURIGA showing that daratumumab plus lenalidomide is a favorable maintenance regimen in multiple myeloma.

Dr Raab on Continued Investigation of Teclistamab Plus Daratumumab-Based Induction in Myeloma

December 2nd 2025

Marc S. Raab, MD, discusses future avenues for the investigation of teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.

Revisit Every OncLive On Air Episode From November 2025

December 2nd 2025

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

OncLive’s November Roundup of Key FDA Approvals in Oncology: 10 Decisions to Know

December 2nd 2025

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026

December 1st 2025

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

FDA Approval of Daratumumab Opens Treatment Options for High-Risk Smoldering Myeloma

December 1st 2025

Peter Voorhees, MD, discusses the FDA approval of daratumumab for patients with high-risk smoldering multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 11/23

November 30th 2025

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

November 28th 2025

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.

Dr Jakubowiak on the Efficacy of KRd Maintenance Therapy Post-ASCT in Multiple Myeloma

November 28th 2025

Andrzej Jakubowiak, MD, PhD, discusses efficacy data with maintenance KRd after ASCT in multiple myeloma.